down arrow

Hubei Biocause Heilen Pharmaceutical Co., Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100005782
CNY
12.62
0.11 (0.88%)

Dec 19

SHE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Hubei Biocause Heilen Pharmaceutical Co., Ltd.
Why is Hubei Biocause Heilen Pharmaceutical Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 20.10%
  • The company has been able to generate a Return on Capital Employed (avg) of 20.10% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of -4.77% and Operating profit at -145.81% over the last 5 years
3
The company has declared negative results for the last 6 consecutive quarters
  • The company has declared negative results in Dec 23 after 4 consecutive negative quarters
  • OPERATING CASH FLOW(Y) Lowest at CNY 79.61 MM
  • PRE-TAX PROFIT(Q) At CNY 4.52 MM has Fallen at -87.02%
  • NET PROFIT(Q) At CNY 4.72 MM has Fallen at -84.08%
4
With ROE of 0.91%, it has a fair valuation with a 2.21 Price to Book Value
  • Over the past year, while the stock has generated a return of 3.57%, its profits have fallen by -83.6%
5
Underperformed the market in the last 1 year
  • The stock has generated a return of 3.57% in the last 1 year, much lower than market (China Shanghai Composite) returns of 15.18%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Hubei Biocause Heilen Pharmaceutical Co., Ltd. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Hubei Biocause Heilen Pharmaceutical Co., Ltd.
-2.41%
0.04
60.33%
China Shanghai Composite
15.44%
1.01
15.10%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
-4.77%
EBIT Growth (5y)
-145.81%
EBIT to Interest (avg)
87.03
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.70
Sales to Capital Employed (avg)
0.23
Tax Ratio
5.98%
Dividend Payout Ratio
78.65%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
20.10%
ROE (avg)
5.00%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
243
Industry P/E
Price to Book Value
2.21
EV to EBIT
-395.42
EV to EBITDA
117.90
EV to Capital Employed
4.95
EV to Sales
7.90
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1.25%
ROE (Latest)
0.91%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company
NET SALES(Q)

Highest at CNY 118.66 MM

-22What is not working for the Company
OPERATING CASH FLOW(Y)

Lowest at CNY 79.61 MM

PRE-TAX PROFIT(Q)

At CNY 4.52 MM has Fallen at -87.02%

NET PROFIT(Q)

At CNY 4.72 MM has Fallen at -84.08%

ROCE(HY)

Lowest at 1.83%

DEBT-EQUITY RATIO (HY)

Highest at -69.23 %

RAW MATERIAL COST(Y)

Grown by 39.09% (YoY

Here's what is working for Hubei Biocause Heilen Pharmaceutical Co., Ltd.
Net Sales
Highest at CNY 118.66 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (CNY MM)

Here's what is not working for Hubei Biocause Heilen Pharmaceutical Co., Ltd.
Pre-Tax Profit
At CNY 4.52 MM has Fallen at -87.02%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (CNY MM)

Net Profit
At CNY 4.72 MM has Fallen at -84.08%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (CNY MM)

Operating Cash Flow
Lowest at CNY 79.61 MM and Fallen
In each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Debt-Equity Ratio
Highest at -69.23 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost
Grown by 39.09% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."